Pheochromocytoma Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Market Impact by DelveInsight | Merck Sharp, Antonio Fojo, Innervate Radiopharma, Advanced Accelerator, Grupo Espan

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pheochromocytoma pipeline constitutes 3+ key companies continuously working towards developing 3+ Pheochromocytoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Pheochromocytoma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pheochromocytoma Market.

The Pheochromocytoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pheochromocytoma Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Pheochromocytoma treatment therapies with a considerable amount of success over the years.

*
Pheochromocytoma companies working in the treatment market are Enterome, Sun Yat-sen University, Antonio Fojo, Innervate Radiopharmaceuticals, Advanced Accelerator Applications, Grupo Espanol de Tumores, Merck Sharp & Dohme LLC, Perspective Therapeutics, and others, are developing therapies for the Pheochromocytoma treatment

*
Emerging Pheochromocytoma therapies in the different phases of clinical trials are- EO2401, Anlotinib and Penpulimab, Lanreotide, 18F-mFBG, Lutetium [177Lu], Cabozantinib, Belzutifan, [212Pb]VMT--NET, and others are expected to have a significant impact on the Pheochromocytoma market in the coming years.

*
In August 2023, HTL-0039732 functions as an EP4 antagonist. By blocking EP4, it inhibits the effects of PGE2, enhancing the immune system's ability to identify and combat cancer cells. This positions HTL-0039732 as a promising candidate for treating cancers that typically do not respond well to existing immunotherapies. The drug candidate is being developed for various cancers, including mesothelioma, sarcoma, and pheochromocytoma.

Pheochromocytoma Overview

Pheochromocytoma is a rare, usually benign tumor that develops in the adrenal glands, which are located on top of the kidneys. These tumors produce excessive amounts of catecholamines, including adrenaline and noradrenaline, leading to symptoms such as high blood pressure, headaches, sweating, rapid heartbeat, and anxiety. While most pheochromocytomas are benign, they can occasionally be malignant (cancerous) and metastasize to other parts of the body.

Get a Free Sample PDF Report to know more about Pheochromocytoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pheochromocytoma-pipeline-insight [https://www.delveinsight.com/report-store/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Pheochromocytoma Drugs Under Different Phases of Clinical Development Include:

*
EO2401: Enterome

*
Anlotinib and Penpulimab: Sun Yat-sen University

*
Lanreotide: Antonio Fojo

*
18F-mFBG: Innervate Radiopharmaceuticals

*
EO2401: Enterome

*
Lutetium [177Lu]: Advanced Accelerator Applications

*
Cabozantinib: Grupo Espanol de Tumores

*
Belzutifan: Merck Sharp & Dohme LLC

*
[212Pb]VMT--NET: Perspective Therapeutics

Pheochromocytoma Route of Administration

Pheochromocytoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Pheochromocytoma Molecule Type

Pheochromocytoma Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Pheochromocytoma Pipeline Therapeutics Assessment

*
Pheochromocytoma Assessment by Product Type

*
Pheochromocytoma By Stage and Product Type

*
Pheochromocytoma Assessment by Route of Administration

*
Pheochromocytoma By Stage and Route of Administration

*
Pheochromocytoma Assessment by Molecule Type

*
Pheochromocytoma by Stage and Molecule Type

DelveInsight's Pheochromocytoma Report covers around 3+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Pheochromocytoma product details are provided in the report. Download the Pheochromocytoma pipeline report to learn more about the emerging Pheochromocytoma therapies [https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Pheochromocytoma Therapeutics Market include:

Key companies developing therapies for Pheochromocytoma are - Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer, Astex Pharmaceuticals, and others.

Pheochromocytoma Pipeline Analysis:

The Pheochromocytoma pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Pheochromocytoma with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pheochromocytoma Treatment.

*
Pheochromocytoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Pheochromocytoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pheochromocytoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pheochromocytoma drugs and therapies [https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Pheochromocytoma Pipeline Market Drivers

*
Increased Research and Development, Advancements in Genetic Testing, Rising Awareness, Government Initiatives, Technological Innovations, Growing Patient Population, are some of the important factors that are fueling the Pheochromocytoma Market.

Pheochromocytoma Pipeline Market Barriers

*
However, High Cost of Treatment, Regulatory Challenges, Limited Patient Population, Side Effects of Treatments, Lack of Awareness, and other factors are creating obstacles in the Pheochromocytoma Market growth.

Scope of Pheochromocytoma Pipeline Drug Insight

*
Coverage: Global

*
Key Pheochromocytoma Companies: Enterome, Sun Yat-sen University, Antonio Fojo, Innervate Radiopharmaceuticals, Advanced Accelerator Applications, Grupo Espanol de Tumores, Merck Sharp & Dohme LLC, Perspective Therapeutics, and others

*
Key Pheochromocytoma Therapies: EO2401, Anlotinib and Penpulimab, Lanreotide, 18F-mFBG, Lutetium [177Lu], Cabozantinib, Belzutifan, [212Pb]VMT--NET, and others

*
Pheochromocytoma Therapeutic Assessment: Pheochromocytoma current marketed and Pheochromocytoma emerging therapies

*
Pheochromocytoma Market Dynamics: Pheochromocytoma market drivers and Pheochromocytoma market barriers

Request for Sample PDF Report for Pheochromocytoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Pheochromocytoma Report Introduction

2. Pheochromocytoma Executive Summary

3. Pheochromocytoma Overview

4. Pheochromocytoma- Analytical Perspective In-depth Commercial Assessment

5. Pheochromocytoma Pipeline Therapeutics

6. Pheochromocytoma Late Stage Products (Phase II/III)

7. Pheochromocytoma Mid Stage Products (Phase II)

8. Pheochromocytoma Early Stage Products (Phase I)

9. Pheochromocytoma Preclinical Stage Products

10. Pheochromocytoma Therapeutics Assessment

11. Pheochromocytoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pheochromocytoma Key Companies

14. Pheochromocytoma Key Products

15. Pheochromocytoma Unmet Needs

16 . Pheochromocytoma Market Drivers and Barriers

17. Pheochromocytoma Future Perspectives and Conclusion

18. Pheochromocytoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pheochromocytoma-pipeline-trends-2024-clinical-trials-therapeutic-innovations-and-market-impact-by-delveinsight-merck-sharp-antonio-fojo-innervate-radiopharma-advanced-accelerator-grupo-espan]
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services



This release was published on openPR.